Amgen Reports observational study Data for Factor D inhibitor in Lupus nephritis

Amgen today announced observational study results for Factor D inhibitor in patients with Lupus nephritis. The study demonstrated that Factor D inhibitor reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Lupus nephritis and support the continued development of Factor D inhibitor in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Factor D inhibitor was consistent with previous observations, with no new safety signals identified.